A Phase III randomized study of interleukin‐2 lymphokine‐activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.